Dr. Maziarz on Unanswered Questions With CAR T-Cell Therapy in DLBCL

Video

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses unanswered questions with CAR T-cell therapy in diffuse large B-cell lymphoma.

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses unanswered questions with CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

Traditionally in DLBCL, physicians expected 15% to 20% of patients to be alive at the 2-year mark. Now, with the emergence of CAR T-cell therapy, researchers expect approximately 40% of patients to be alive at the 2-year mark. This is encouraging because a survival of at least 2 years indicates long-term survival, Maziarz says. However, that still leaves 60% of patients who need effective therapy. Therefore, a better understanding of what drives resistance is crucial.

Moreover, CAR T-cell therapy is associated with unique toxicities, and researchers need to make the treatment safer so more patients can receive it. For example, a proliferation event can occur as a result of cells growing fast.

Recent Videos
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
© 2025 MJH Life Sciences

All rights reserved.